

# Optimising DNA vaccine technology to prevent HIV-1 infection

Tessa Gargett BA BSc(Hons)

VIROLOGY LABORATORY, BASIL HETZEL INSTITUTE FOR TRANSLATIONAL HEALTH RESEARCH

DEPARTMENT OF MEDICINE, FACULTY OF HEALTH SCIENCES

SUBMITTED FOR DOCTORATE OF PHILOSOPHY MAY 2013



# Abstract

The failure of traditional protein-based vaccines to prevent HIV infection highlights the need for novel vaccine strategies. An effective HIV-1 vaccine will need to induce cell-mediated and humoral immune responses at both systemic and mucosal sites.

DNA based vaccines are appealing candidates for novel vaccines because they are inexpensive, stable and simple to manufacture. They also mimic a viral infection, by using cellular machinery to produce vaccine antigens in the same way that viruses hijack the host cell to produce viral proteins and nucleic acids, but are not infectious themselves. DNA vaccines effectively induce both humoral and cell mediated immune responses to viral antigens, however despite being licensed for veterinary use they have so far been insufficiently immunogenic in human trials.

To realise the potential of DNA vaccines, the technology must first be optimised to improve both delivery and immunogenicity. In this thesis I have proposed two novel approaches to optimise DNA vaccines. Firstly, to improve delivery, I have proposed the use of influenza virosomes as a delivery vehicle for the intranasal administration of DNA vaccines. Intranasal vaccination is known to induce pan-mucosal immune responses at distant sites such as the genital mucosa. This concept is particularly important for HIV vaccines, as it is believed that an early immune response at the genital mucosa offers the best chance to control HIV infection before it becomes systemic. In this thesis I have used live imaging of the reporter molecule, luciferase, to confirm efficient intranasal delivery of DNA vaccines by influenza virosomes, and this is the first time that visualisation of this process has been reported. I have also demonstrated that intranasal delivery of virosome-encapsulated DNA can enhance the mucosal immune response.

Secondly, to improve immunogenicity, I have proposed the use of suicide genes to induce cell necrosis and provide an adjuvant effect for DNA vaccines. Necrotic, antigen-positive cells release a range of intracellular factors that signal via receptors on dendritic cells, including Toll-like receptors and Clec9A, and lead to dendritic cell activation and enhanced cross-presentation of antigen. In this thesis I have tested the novel application of the suicide genes NSP4, perforin (PRF) and DTa, which induce cell death by different mechanisms. I have provided evidence that suicide gene-induced necrosis in DNA vaccine-targeted cells provides an adjuvant effect. In this thesis I report that a DNA vaccine that induces cytolytic, rather than apoptotic, cell death enhances CD11c<sup>+</sup> CD8 $\alpha$ <sup>+</sup> dendritic cell activation, broad and multifunctional CD8 T cell responses

and increases protection in mice from challenge with a chimeric virus, EcoHIV. This enhancement was also dependent on the timing of cell death after antigen expression. Thus, cytolytic gene-induced necrosis resulting from co-expression of perforin and an immunogenic protein can significantly improve the immunogenicity of DNA vaccines.

The work in this thesis therefore describes the development of a novel intranasal delivery system and a novel adjuvant system that advance DNA vaccine technology, and improve the potential for DNA to be used as an effective vaccine for HIV-1.

# Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Tessa Gargett.

# Acknowledgments

I would first like to acknowledge and thank my principal supervisor Professor Eric Gowans for his assistance in designing the experiments and analysing the data presented in this thesis, and for his extensive help with editing manuscripts and this thesis. I would also like to thank my co-supervisors Dr. Branka Grubor, Dr. Darren Miller and Professor Chris Burrell for all their help in designing the experiments and analysing the data presented in this thesis. I would particularly like to thank Dr. Darren Miller for the extensive technical training he provided at the beginning of this project in terms of cloning, virosome preparation, animal handling, live imaging, and immunological assays. Dr. Darren Miller also performed the initial experiments that established the formulation of the influenza virosomes in our laboratory.

I would next like to thank all other past and present members of the Virology Lab. In particular, I would like to thank Stanley Yu for his assistance with data analysis and with my lab work, including the isolation of mucosal draining lymph nodes, and Tamsin Garrod for her ongoing practical and moral support during my PhD, including assistance with mouse handling, protein purification, peptide pool preparation and EcoHIV production. Some of the work described in this thesis is based on her initial observations (of the cytotoxicity of perforin) during her Masters. In addition, the perforin and DTa genes were sub-cloned from DNA constructs originally generated by Hugh Trahair during his Masters.

I would like to thank Don Anson, Ilia Voskoboinik, Barbara Coulson, Ehud Hauben, Steve Wesselingh, Joe Toressi, Bruce Loveland, Phillippe LaTour, Andreas Suhrbier, Guy Madden, Shaun McColl and Simon Barry for contributing reagents and/or advice on this project, and on my PhD candidature in general.

I would like to thank Lee Major for technical assistance with the EcoHIV model, Trish Cmielewski and Ruth Williams for technical assistance with the live imaging, Lynn Marsden for technical assistance at the Women's and Children's Hospital animal house, and Jing Ou for statistical analysis.

Finally, I would like to thank my partner Tim Lucas, and my family and friends, for their continual love, support and friendship throughout my PhD.

## Abbreviations

(r)Ad5	(recombinant) Human adenovirus type 5
ADCC	antibody-dependent cell-mediated cytotoxicity
ADCVI	antibody-dependent cell-mediated viral inhibition
AIDS	Acquired Immunodeficiency Syndrome
bp	base pairs
CFSE	Carboxyfluorescein diacetate succinimidyl ester
CD	Cluster of Differentiation
DAMPs	Damage-associated molecular patterns
DC	Dendritic Cell
DMEM	Dulbecco's Modified Eagle Media
DTa	Diphtheria toxin subunit A
EcoHIV	Ecotropic Human Immunodeficiency Virus (HIV envelope replaced with envelope from murine leukemia virus)
ELISA	Enzyme linked Immuno-sorbent Assay
ELISPOT	Enzyme linked Immuno-sorbent Spot Assay
<i>env</i>	HIV-1 <i>env</i> gene encoding DNA sequence for expression of the envelope glycoprotein
env/ENV	HIV-1 envelope gp160 protein that is cleaved into: gp120 surface unit and gp41 transmembrane domain
FCS	Fetal Calf Serum
<i>gag</i>	HIV-1 <i>gag</i> gene encoding DNA sequence for expression of gag protein
gag/GAG	HIV-1 p55 gag polyprotein that is cleaved into: p24 capsid, p17 matrix and P7 nucleocapsid
GCV	gancyclovir
GFP	green fluorescent protein
HBS	Hanks buffered Saline
HIV	Human Immunodeficiency Virus
HSV-TK	Herpes simplex virus thymidine kinase
ID	Intradermal injection or vaccination
i.d.	immuno-dominant
IFN-	Interferon
IL-	Interleukin
IM	Intramuscular injection or vaccination

IN	Intranasal vaccination
IP	Intraperitoneal injection or vaccination
IR	Intrarectal vaccination
Iva	Intravaginal vaccination
kb	kilo base
kDa	kilo Dalton
LAV	live attenuated virus
LUC	firefly luciferase
MVA	Modified vaccinia Ankara
NSP4	non-structural protein 4
PAMPs	Pathogen-associated molecular patterns
PBS	Phosphate buffered Saline
PEC	Peritoneal exudate cells
PI	Propidium Iodide
<i>pol</i>	HIV-1 <i>pol</i> gene encoding DNA sequence for expression of pol protein
pol/POL	HIV-1 p110 pol polyprotein that is cleaved into: p11 protease, p66/51 reverse transcriptase and p35 integrase
PRF	Perforin
RBC	Red Blood Cells
RES	Restriction enzyme site
RPMI	Roswell Park Memorial Institute Media
SC	Subcutaneous injection or vaccination
SIV	Simian Immunodeficiency Virus
SFU	Spot forming units
TLR	Toll-like receptor
TNF-	Tumour Necrosis Factor

# Table of Contents

<b>Abstract</b> .....	<b>iii</b>
<b>Declaration</b> .....	<b>v</b>
<b>Acknowledgments</b> .....	<b>vi</b>
<b>Abbreviations</b> .....	<b>vii</b>
<b>Table of Contents</b> .....	<b>ix</b>
<b>Chapter 1 - Introduction</b> .....	<b>1</b>
<b>1.1 An Overview of Vaccination</b> .....	<b>1</b>
<b>1.1.2 Vaccines to induce humoral vs. cell-mediated Immunity</b> .....	<b>4</b>
Innate immunity .....	5
Adaptive humoral immunity .....	7
Adaptive cellular immunity .....	7
<b>1.2 Human Immunodeficiency Virus (HIV)</b> .....	<b>9</b>
<b>1.2.1 Pathogenesis and epidemiology of HIV</b> .....	<b>9</b>
<b>1.2.2 Overview of the molecular biology of HIV</b> .....	<b>11</b>
The HIV genome and virion .....	11
<b>1.2.3 The Course of HIV infection</b> .....	<b>13</b>
Early infection .....	13
Acute infection .....	14
Persistent infection and AIDS .....	16
<b>1.2.4 The HIV-specific immune response</b> .....	<b>17</b>
Long-term Non-Progressors .....	17
Exposed, HIV negative individuals .....	19
The Simian Immunodeficiency Virus model .....	20
<b>1.2.5 Prevention and treatment of HIV</b> .....	<b>22</b>
Antiretroviral therapy and therapeutic vaccines.....	22
Preventative strategies.....	23
<b>1.3 HIV Vaccine Clinical trials</b> .....	<b>24</b>
<b>1.3.1 The AIDSVAX Trial</b> .....	<b>24</b>
<b>1.3.2 The Step Trial</b> .....	<b>26</b>
Rationale .....	26
Pre-clinical testing.....	27
The clinical trials .....	28
Follow up studies .....	29
<b>1.3.3 The RV144 Trial</b> .....	<b>31</b>
Rationale .....	31
Pre-clinical testing.....	32
The clinical trials .....	33
Follow up studies .....	34
<b>1.3.4 Phase 1 and 2 clinical trials</b> .....	<b>35</b>
<b>1.4 Novel Vaccine Research</b> .....	<b>37</b>
<b>1.4.1 DNA vaccines</b> .....	<b>37</b>
Improving expression .....	40
Improving delivery - Liposomes and Virosomes .....	40
Improving delivery – Gene-gun, Electroporation and DNA tattooing.....	41
Improving immunogenicity.....	42
<b>1.4.2 Recombinant viral vaccines</b> .....	<b>44</b>
Adenovirus vectors .....	44
Poxvirus vectors .....	46

Other viral vectors .....	47
<b>1.4.3 Routes of vaccination.....</b>	<b>49</b>
Intramuscular route.....	49
Subcutaneous and intradermal routes .....	49
Mucosal routes .....	51
<b>1.4.4 Adjuvants .....</b>	<b>54</b>
Cytokines and other immune-stimulatory factors .....	55
Dendritic cell targeted adjuvants .....	57
<b>1.4.5 Suicide genes as adjuvants.....</b>	<b>58</b>
Apoptosis and necrosis.....	58
Suicide genes as cancer therapy .....	61
Suicide genes as adjuvants for vaccines.....	62
<b>1.5 Experimental Aims.....</b>	<b>64</b>
<b>Chapter 2 – Materials and Methods.....</b>	<b>65</b>
<b>2.1 DNA vaccine construction.....</b>	<b>65</b>
pVAX commercial plasmid .....	65
Bi-cistronic pVAX plasmid.....	65
PCR primer design for gene amplification .....	66
Digestion and ligation .....	67
DNA sequencing.....	67
Luciferase assays.....	68
Immuno-blotting .....	68
Trypan blue counts for suicide gene induced cell death.....	69
Detection of necrosis by Propidium Iodide and Annexin V flow cytometry .....	69
Preparation of DNA vaccine stocks .....	70
<b>2.2 Virosome formulation and testing <i>in vitro</i> .....</b>	<b>70</b>
Influenza virus propagation .....	70
HA protein gel and western blots.....	70
Hemagglutination assays .....	71
Virosome formulation.....	71
Virosome extrusion .....	72
GFP fluorescence microscopy.....	72
GFP flow cytometry .....	72
<b>2.3 Mouse vaccination and challenge .....</b>	<b>72</b>
Mice .....	72
Anaesthetic .....	72
Blood collection .....	73
Lavage collection .....	73
Spleen and lymph node collection .....	73
Peritoneal macrophage collection .....	74
Intradermal vaccination.....	74
Intranasal vaccination.....	75
Intramuscular and subcutaneous vaccination .....	75
Live imaging .....	75
EcoHIV challenge model.....	76
<b>2.4 Immunological Assays .....</b>	<b>77</b>
Recombinant protein production and purification .....	77
IgG ELISA and uric acid testing .....	78
Peptide formulations .....	78
ELISPOT.....	79
Intracellular Cytokine Staining (ICS) and flow cytometry .....	79
Dendritic cell flow cytometry .....	80
CFSE proliferation flow cytometry .....	80
Memory T cell population flow cytometry.....	81

Histology .....	81
EcoHIV replication assay .....	81
Statistical analysis .....	82
<b>Chapter 3. Virosomes for the intranasal delivery of DNA vaccines .....</b>	<b>83</b>
<b>3.1 Introduction.....</b>	<b>83</b>
The intranasal delivery route .....	83
Luciferase as a model vaccine antigen.....	84
<b>3.2 Virosome formulation .....</b>	<b>85</b>
Virosomes contain membrane-bound influenza HA molecules .....	85
Virosomes contain encapsulated DNA.....	88
<b>3.3 Testing virosomes <i>in vitro</i>.....</b>	<b>90</b>
Virosomes transfect HEK293T and A549 cell lines <i>in vitro</i> .....	90
Virosomes are stable at 4°C.....	92
Virosome extrusion reduces the cellular toxicity .....	93
<b>3.4 Testing virosomes <i>in vivo</i> .....</b>	<b>95</b>
Virosomes and naked DNA transfect the ear dermis .....	96
Only virosomes transfect the nasal epithelia.....	97
The duration of antigen expression varies for different vaccination routes .....	101
<b>3.5 Immune responses following virosome vaccination .....</b>	<b>102</b>
Virosomes cannot be used for booster vaccinations .....	102
Intranasal prime, intradermal boost induces systemic and mucosal antibody.....	105
Intranasal prime, intradermal boost induces systemic and mucosal T cell responses .....	106
<b>3.6 Summary .....</b>	<b>107</b>
<b>Chapter 4. Optimisation of suicide genes as adjuvants for DNA vaccination. ....</b>	<b>109</b>
<b>4.1 Introduction.....</b>	<b>109</b>
Previous studies into cell death and vaccination .....	109
Intradermal delivery and dendritic cells .....	110
Suicide gene adjuvants .....	111
<b>4.2 Candidate suicide gene testing <i>in vitro</i> .....</b>	<b>112</b>
Design of DNA vaccines to encode an antigen and suicide gene .....	112
Suicide genes induce cell death <i>in vitro</i> .....	113
Trypan blue staining for viability .....	115
Luciferase assays to track cell death .....	116
Flow Cytometry to detect apoptosis and necrosis .....	118
<b>4.3 Effects of suicide gene expression on luminescence <i>in vivo</i> .....</b>	<b>122</b>
Tracking luminescence <i>in vivo</i> to identify luciferase-positive cell death.....	122
<b>4.4 Effects of suicide gene expression on the luciferase-specific immune response .....</b>	<b>126</b>
The humoral immune response to luciferase.....	127
The cell-mediated immune response to luciferase .....	128
<b>4.5 Evidence for suicide gene-induced necrosis and DC activation .....</b>	<b>129</b>
Histology to identify necrosis and inflammation in the ear dermis .....	130
DC populations and activation in the draining lymph node.....	132
<b>4.6 Summary .....</b>	<b>137</b>
<b>Chapter 5. Suicide gene adjuvants to enhance the immune response to HIV-1 viral antigens.....</b>	<b>140</b>
<b>5.1 Introduction.....</b>	<b>140</b>
GAG as an HIV-1 vaccine antigen .....	140
Methods to examine cell-mediated immune responses.....	140

<b>5.2 Design and testing of gag DNA vaccines <i>in vitro</i></b> .....	<b>141</b>
DNA vaccines encoding HIV-1 antigens and a suicide gene candidate.....	141
<b>5.3 Cell-mediated immune responses to GAG DNA vaccines</b> .....	<b>145</b>
GAG peptide pools for immuno-assays.....	145
ID DNA vaccination to induce GAG-specific immune responses .....	146
The effect of suicide gene adjuvants on IFN $\gamma$ ELISPOT responses to GAG.....	147
<b>5.4 Multi-functional cell-mediated immune responses to GAG DNA vaccines</b> .....	<b>150</b>
The effect of suicide gene adjuvants on multiple cytokine secretion.....	151
The effect of suicide gene adjuvants on cell proliferation.....	156
<b>5.3 Humoral immune responses to GAG DNA vaccines</b> .....	<b>157</b>
The effect of suicide gene adjuvants on capsid- (p24) and matrix- (p17) specific antibody responses .....	158
<b>5.4 Summary</b> .....	<b>159</b>
<b>Chapter 6. Vaccine-induced protection against EcoHIV challenge</b> .....	<b>163</b>
<b>6.1 Introduction</b> .....	<b>163</b>
The EcoHIV model .....	164
<b>6.2 Optimisation of the EcoHIV challenge model <i>in vitro</i> and <i>in vivo</i></b> .....	<b>165</b>
Propagation and testing of EcoHIV <i>in vitro</i> .....	165
EcoHIV replication <i>in vivo</i> .....	167
<b>6.3 Protection against EcoHIV challenge</b> .....	<b>168</b>
<b>6.4 Suicide gene technology provides increased protection against EcoHIV challenge</b> .....	<b>169</b>
The effect of pVAX GAG PRF vaccination on EcoHIV challenge .....	170
Immune responses after EcoHIV challenge.....	171
<b>6.5 Long-term protection from EcoHIV challenge</b> .....	<b>174</b>
The effect of pVAX GAG PRF vaccination on a long-term EcoHIV challenge .....	175
Immune responses after long-term EcoHIV challenge .....	176
<b>6.6 Summary</b> .....	<b>180</b>
<b>Chapter 7. Discussion</b> .....	<b>183</b>
<b>7.1 Introduction</b> .....	<b>183</b>
Novel vaccine strategies for HIV-1 .....	183
DNA vaccines for HIV-1 .....	185
<b>7.2 Virosomes for the intranasal delivery of DNA vaccines</b> .....	<b>189</b>
Virusome delivery of DNA vaccines improved the mucosal immune response .....	189
The potential of virosomes to be used for delivery of DNA vaccines.....	190
<b>7.3 Suicide genes as adjuvants for DNA vaccines</b> .....	<b>192</b>
The importance of the mechanism and timing of suicide gene-induced cell death .....	192
Limitations and future work for suicide-gene adjuvants .....	193
Suicide genes can either enhance or inhibit the immune response to GAG .....	195
The EcoHIV challenge model for testing HIV-1 vaccines in mice.....	197
The potential for suicide genes to be used as adjuvants for DNA vaccines .....	199
<b>7.4 Conclusions</b> .....	<b>200</b>
<b>Appendices</b> .....	<b>202</b>
<b>Appendix A. Table of primer sequences</b> .....	<b>202</b>
<b>Appendix B. Table of plasmid DNA constructs used in this thesis</b> .....	<b>203</b>

<b>Appendix C. Examples of the mouse clinical record sheet and the mouse weight measurements .....</b>	<b>204</b>
<b>Appendix D. GAG peptides .....</b>	<b>205</b>
<b>Appendix E. Purification of recombinant his-tagged p24 .....</b>	<b>206</b>
<b>Appendix F. QPCR primer amplification efficiencies, melt curves and quantification curves for RPL13a and MLV.....</b>	<b>207</b>
<b>Bibliography .....</b>	<b>208</b>